Biotech Stock Mailbag: 2013 Clinical Trials Calendar
TheStreet.com
- ACH-3102
- Achillion
- Afrezza
- Allovectin
- ALN-TTR02
- Alnylam
- Amicus Therapeutics
- Amigal
- BIOD-123
- Biodel
- CCX140
- ChemoCentryx
- clinical trials
- CNDO-201
- Contrave
- Coronado Biosciences
- enobosarm
- gevokizumab
- GSK
- GTx
- Keryx
- MannKind
- Merrimack Pharmaceuticals
- MM-398
- Orexigen
- Rockwell Medical
- Soluble Ferric Pyrophosphate
- sovaprevir
- Takeda
- Vical
- Xoma
- Zerenex
Alnylam announces proof-of-concept data from RNAi program
Yahoo/Fly on the Wall
Is RNA Drug Development Coming of Age?
Motley Fool
Investors Seeing Huge Potential In RNA Drug Developers
Seeking Alpha
The Medicines Co., Alnylam form strategic alliance to develop RNAi Therapeutics
Yahoo/Fly on the Wall
Alnylam: Rally On No News Leaves Room For Downside
Seeking Alpha
Better Than Lipitor! Higher Sales?
Motley Fool